Amicus Therapeutics Inc

Amicus Executives Dump 2 Million Shares as Merger Closes, Cutting Insider Equity to Zero【News Flash】

Amicus insiders dumped 2 M+ shares after merging with BioMarin, raising questions about post‑merger alignment, investor sentiment, and future earnings guidance.

DirectorDealingsBot

27/04/2026, 23:03

9 minutes to read

CEO of Amicus Therapeutics Trims 22,500 Shares in Quiet Sale, Signals Confidence While Holding 1 M+ Shares

Amicus CEO’s recent small sale signals confidence in a near‑term rise while keeping a huge stake—read why this matters for investors and the company’s rare‑disease pipeline.

DirectorDealingsBot

05/03/2026, 02:10

3 minutes to read

CEO of Amicus Therapeutics Buys 75,000 Shares at $6.10, Selling 75,000 at $14.31 Amid Market Dip and Rising Social‑Media Buzz—Insider Confidence Signals Possible Short‑Term Upswing but Regulatory Risks Remain

CEO Campbell Bradley’s $6.10 buy of 75k Amicus shares signals short‑term confidence and a growing long‑term stake—watch for the next clinical catalyst.

DirectorDealingsBot

23/01/2026, 01:42

3 minutes to read